Patents matching “antibody”

US 11535869

CD8-specific antibody constructs and compositions thereof

Sana Biotechnology, Inc. · Granted Dec 27, 2022 · Expires Dec 22, 2042

US 11518804

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Dec 6, 2022 · Expires Dec 1, 2042

US 11518800

Mutations that drive VH4 antibody autoreactivity

The Board of Regents of the University of Texas System · Granted Dec 6, 2022 · Expires Dec 1, 2042

US 11505601

Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum

Nanjing Legend Biotech Co., Ltd · Granted Nov 22, 2022 · Expires Nov 17, 2042

US 11485793

Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

US 11472884

Humanized BCMA antibody and BCMA-CAR-T cells

Caribou Biosciences, Inc. · Granted Oct 18, 2022 · Expires Oct 13, 2042

US 11459381

Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof

UNIVERSITY OF CONNECTICUT · Granted Oct 4, 2022 · Expires Sep 29, 2042

US 11453725

Methods for DNA-dependent targeting of a cell permeant antibody

United States Government as represented by the Department of Veterans Affairs · Granted Sep 27, 2022 · Expires Sep 22, 2042

US 11433029

Formulation of an antibody and use thereof

Takeda Pharmaceutical Company Limited · Granted Sep 6, 2022 · Expires Sep 1, 2042

US 11434300

Methods and antibody compositions for tumor treatment

REGENERON PHARMACEUTICALS, INC. · Granted Sep 6, 2022 · Expires Sep 1, 2042

US 11427634

Human anti-semaphorin 4D antibody

VACCINEX, INC. · Granted Aug 30, 2022 · Expires Aug 25, 2042

US 11421036

Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)

REGENERON PHARMACEUTICALS, INC. · Granted Aug 23, 2022 · Expires Aug 18, 2042

US 11421034

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Five Prime Therapeutics, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

US 11407825

NaPi2b-targeted polymer antibody-drug conjugates and methods of use thereof

Mersana Therapeutics, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

US 11389480

Human monoclonal antibody targeting TNFR2 for cancer immunotherapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 19, 2022 · Expires Jul 14, 2042

US 11390682

Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy

Dyne Therapeutics, Inc. · Granted Jul 19, 2022 · Expires Jul 14, 2042

US 11384139

Antibody targeting cell surface deposited complement protein C3d and use thereof

THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Jul 12, 2022 · Expires Jul 7, 2042

US 11384098

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA · Granted Jul 12, 2022 · Expires Jul 7, 2042

US 11370836

Monoclonal antibody binding to human IL-5, preparation method therefor and use thereof

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Jun 28, 2022 · Expires Jun 23, 2042

US 11364298

Photosensitizing antibody-fluorophore conjugates

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 21, 2022 · Expires Jun 16, 2042

US 11365265

Anti-C5 antibody combinations and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Jun 21, 2022 · Expires Jun 16, 2042

US 11364297

Photosensitizing antibody-fluorophore conjugates

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 21, 2022 · Expires Jun 16, 2042

US 11338037

Ultrastable antibody ionic liquids

United States of America as represented by the Secretary of the Air Force · Granted May 24, 2022 · Expires May 19, 2042

US 11324822

Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Syndax Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042